Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

SPARC Spatial profiling of gastric cancer with peritoneal carcinomatosis to tackle cancer spreading and improve precision immuno-oncology

Coordinator
Karolinska Institutet, Sweden
Runs
1 May 2026 to 30 April 2028
Status
Running
EU funding
€236k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101208925

What the project is doing

In the project's own words, from its summary on CORDIS.

The SPARC project tackles the urgent challenge of poorly cohesive gastric cancer (PCGC) with peritoneal carcinomatosis — an aggressive malignancy associated with a 5-year survival rate <30%. Despite advancements in GC treatment, effective therapies for PCGC with peritoneal spread remain inadequate, largely due to the tumor’s resistance to chemotherapy and the complex tumor microenvironment. This microenvironment is involved in hijacking cancer immune surveillance and supporting tumour outgrowth and invasion.

However, the detailed molecular and spatial dynamics promoting PCGC dissemination are not yet fully understood. The project aims to fill this gap and elucidate the molecular and cellular mechanisms driving this aggressive behavior by employing advanced spatial immunofluorescence (IF) imaging and spatial transcriptomics to map the tumor and immune microenvironment of PCGC with synchronous peritoneal metastases, leveraging a rare biobank of treatment-naïve PCGC samples.

This will enable to better understand the complex cellular interactions that drive tumor growth, immune evasion, and metastasis, as well as identify and validate - at both protein and gene expression levels - novel biomarkers specifically associated with peritoneal metastasis, serving as potential therapeutic and prognostic targets for this challenging cancer subtype. The project leverages an interdisciplinary collaboration between leading research institutions – Karolinska Institutet (Sweden, host institution), Yale University (USA, secondment institution), University Hospital of Verona (Italy, collaboration partner) – and is supported by renowned experts in immuno-oncology and GC that will provide multidisciplinary training to the researcher, enhancing their career prospects while addressing a significant unmet medical need.

Topics

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator
Yale UniversityNew HavenUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI